- Conditions
- Amyotrophic Lateral Sclerosis
- Interventions
- Placebo (Part A), CK-2017357 (Part A), Riluzole 50 MG (Part B), Placebo (Part B), CK-2017357 (Part B)
- Drug
- Lead sponsor
- Cytokinetics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 9
- States / cities
- San Francisco, California • Jacksonville, Florida • Kansas City, Kansas + 6 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–8
of 8
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Amyotrophic Lateral Sclerosis
- Interventions
- CK-2017357, Placebo, Riluzole 50 MG
- Drug
- Lead sponsor
- Cytokinetics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 11
- States / cities
- Fresno, California • La Jolla, California • Orange, California + 8 more
- Conditions
- Amyotrophic Lateral Sclerosis (ALS)
- Interventions
- tirasemtiv
- Drug
- Lead sponsor
- Cytokinetics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 280 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 41
- States / cities
- Phoenix, Arizona • Los Angeles, California • Orange, California + 36 more
- Conditions
- Intermittent Claudication, Peripheral Artery Disease
- Interventions
- Placebo, 375 mg CK-2017357, 500 mg CK-2017357
- Drug
- Lead sponsor
- Cytokinetics
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 14
- States / cities
- Phoenix, Arizona • Santa Ana, California • Stanford, California + 11 more
- Conditions
- Amyotrophic Lateral Sclerosis
- Interventions
- Placebo, 250 mg CK-2017357, 500 mg CK-2017357
- Drug
- Lead sponsor
- Cytokinetics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 67 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010
- U.S. locations
- 15
- States / cities
- Phoenix, Arizona • Fresno, California • San Francisco, California + 12 more
- Conditions
- Myasthenia Gravis
- Interventions
- Placebo, 250 mg CK-2017357, 500 mg CK-2017357
- Drug
- Lead sponsor
- Cytokinetics
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 15
- States / cities
- Fresno, California • Orange, California • San Francisco, California + 12 more
- Conditions
- Amyotrophic Lateral Sclerosis
- Interventions
- CK-2017357, Placebo tablets, Riluzole
- Drug · Other
- Lead sponsor
- Cytokinetics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 711 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 44
- States / cities
- Phoenix, Arizona • La Jolla, California • Orange, California + 38 more
- Conditions
- Amyotrophic Lateral Sclerosis
- Interventions
- Tirasemtiv, Placebo tablets
- Drug
- Lead sponsor
- Cytokinetics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 744 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 49
- States / cities
- Phoenix, Arizona • La Jolla, California • Los Angeles, California + 42 more